Analysts Set Personalis, Inc. (NASDAQ:PSNL) Price Target at $10.86

Personalis, Inc. (NASDAQ:PSNL) has received an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $10.8571.

Several research analysts have recently commented on PSNL shares. Lake Street Capital reissued a “buy” rating and set a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th. Needham & Company LLC lifted their target price on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Morgan Stanley boosted their price target on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a report on Saturday, January 31st.

Insider Transactions at Personalis

In other news, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the transaction, the chief financial officer directly owned 164,458 shares in the company, valued at approximately $1,772,857.24. This represents a 38.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.80% of the stock is currently owned by company insiders.

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently bought and sold shares of the company. ARK Investment Management LLC raised its stake in shares of Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after acquiring an additional 802,268 shares in the last quarter. AIGH Capital Management LLC boosted its stake in shares of Personalis by 4.5% in the 3rd quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock valued at $25,376,000 after purchasing an additional 168,143 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after purchasing an additional 861,948 shares during the last quarter. Kennedy Capital Management LLC raised its position in Personalis by 196.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after purchasing an additional 1,281,695 shares during the period. Finally, Blue Water Life Science Advisors LP raised its position in Personalis by 42.6% in the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock worth $10,997,000 after purchasing an additional 500,900 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Stock Down 2.1%

Personalis stock opened at $8.21 on Friday. The stock has a market cap of $729.05 million, a price-to-earnings ratio of -9.33 and a beta of 1.98. The business has a 50-day simple moving average of $8.82 and a 200 day simple moving average of $7.77. Personalis has a 52 week low of $2.83 and a 52 week high of $11.50.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.